PPIDT00426
Drug Information
| Name | Pozelimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15218 |
| Type | biotech |
| Indication | Pozelimab is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.[L47850] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous; Subcutaneous |
200 mg/1mL
|